End-Stage Renal Failure Clinical Trial
Official title:
A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy
Anaemia is a common complication of Chronic Kidney Disease (CKD) the management of which has
been aided by the use of synthetic recombinant human erythropoietin therapy (r-HuEPO). This
red cell stimulating agent creates the further complication of Functional Iron Deficiency
(FID) where, despite normal iron stores, patients fail to respond to therapy as they do not
possess enough available iron to meet the demand of increased red cell production. Effective
response to r-HuEPO therapy depends on an appropriate monitoring of 'available' iron levels.
Previous research into the clinical utility of testing for reticulated haemoglobin
concentrations (Ret He) instead of Serum Ferritin and Transferrin Saturation analysis has
indicated an advantage as an iron deficient prognostic marker however, further knowledge is
required on the use of this new laboratory test (RetHe) to predict Functional Iron Deficiency
(FID) level and to study it's relationship with responses to therapy.
This proposed study aims to estimate a local working Normal (non deficient) and Iron
Deficient Reticulated Haemoglobin Content (RET He) reference range from surplus anonamous
samples. Routine monthly blood samples from Pre Dialysis and Haemodialysis patients will be
used to evaluate the sensitivity and specificity of the RET He test compared to current
laboratory tests and investigate its predictive ability for Functional Iron Deficiency in
these patients.
Studying , measuring and statistically analysing the change in the RET He parameters in
Haemodialysis and Pre Dialysis patients over 3 months will look for evidence of a direct
relationship between RET He values and the patients response to therapy. The data will be
used to provide a predictive picture of what levels of RET He indicate Functional Iron
Deficiency.
The introduction of this test (RetHe) may provide clinicians with a one sample/one test
control over iron therapies and ensure the patient gets the most benefit from erythropoietin
therapy.
Reference Range Testing for new test RET-He will be performed on excess blood available on
randomly selected anonamised samples obtained from the daily workload of the laboratory once
all the clinically requested analysis has been completed.
100 samples (50 men / 50 women)determined to have normal parameters(as defined by Dacie et
al, 10th Edition) and 100 samples (50 men / 50 women)determined to be iron deficient (as
defined by Dacie et al, 10th Edition)will be processed for new test parameter (RetHe) under a
coded number to ensure no identifying data is recorded. The samples will be archived and and
held within the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste
Management Policy.The data will be analysed using a paired t test to determine significant
differences and reference range inferred inferred.
Evaluation of sensitivity / specificity of new Ret He test in determinimg iron deficiency and
functional iron deficiency and it's response to terapy will be tested using Haemodialysis and
Pre-Dialysis Patient Samples (~180 Haemodialysis Patients and ~250 Pre Dialysis Patients)that
are obtained during their normal renal unit / clinic appointments.
All consenting NHS Fife Haemodialysis /Pre Dialysis patients will be allocated a 'Subject
Identification Number' as part of this study (which will be noted at the top of their Consent
Form). This number will be used by the Student Investigator to generate a confidential Coding
Key which will be kept separate from data information and secure uner an NHS password
protected computer. This will ensure care of personal information and will be used
through-out the study by the student investigator to record all generated data.
Patients will be grouped into categories such as Dialysis / Pre Dialysis on a coded SPSS
(statistical software) file.
All consenting patients will attend their routine scheduled Renal Clinic appointments as
normal (no additional appointments are necessary for this pilot study)and their response to
therapy will be observed using the new RetHe test parameter compared to existing laboratory
tests utlised (FBC,Ferritin and Transferrin Saturation Levels)
Haemodialysis Patients - June 2010, July 2010*, August 2010
(* NB: In July 2010 Haemodialysis patients are scheduled to have their Ferritin and
Transferrin Saturation Levels checked and therfore no additional sample will be required)
1. Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test
2. Routine venesection of Clotted (yellow topped) sample for Biochemistry Analysis
3. Additional venesection of extra yellow topped sample for non routine Ferritin
Test(*usually scheduled every 3 months- routine date due: July 2010)
4. Renal Unit Staff label samples and complete request form:
Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of
new Ret He test to FBC analysis) and Ferritin (additional request in June and August)
Biochemistry section ticked for : All routinely requested Biochemistry tests (such as
Urea and Electrolytes) plus additional request for Transferrin Saturation Levels (in
June and August)
5. Sample and Requests sent to Fife Area Lab for Analysis
The project will be carried out within NHS Fife Area Laboratory Haematology Department
and will involve the use of NHS premises, facilities and staff.
6. Request checked at Laboratory Central Reception (sample and request form labelled with
unique positive barcode identification)
7. Request Forms sent to central request entry and samples delivered to appropriate
laboratories
8. FBC samples checked prior to analysis to check request details entered into Laboratory
Host Computer System
9. FBC sample loaded onto Sysmex XE2100 Haematology Analyser for testing
10. Bidirectional Computer Link between Laboratory Host Computer System and Analyser ensures
sample tested for FBC and additionally requested RETIC (reticulocyte analysis)
11. Sysmex XE2100 automatically analyses sample for Red Blood Cell Indices and additionally
uses fluorescent polymethine dye to stain for RNA/DNA content of reticulated cells
(early red blood cell precursors). The analyser uses inbuilt Flow Cytometry and measures
forward scatter to separate cells by size (this is reported as RBC-Y and RET-Y)
12. Sysmex XE2100 RETIC Master software (recently upgraded packaged loaded onto NHS Fife
Analysers)uses an algorithm (RET-He = 5.5569e 0.001RET-Y) to convert RET-Y into a
reportable mean reticulocyte haemoglobin content (RET He) which is expressed in
picograms.
13. The sample once analysed is removed from the analyser and the results are either
autovalidated and archived (if results are within normal range) or held for validation
by a NHS Fife qualified Biomedical Scientist.
14. The routinely requested FBC results are available for clinicians within same timescale
as normal (no delay due to additional RetHe analysis)
15. The sample is archived under their unique identifying barcode numbers and held within
the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste
Management Policy.
16. The new RetHe value will be held on Sysmex XE2100 analyser (not activated as a
reportable test to NHS Fife Biomedical Scientists or clinical staff.)
17. The Student Investigator will (on same day as analysis) retrospectively generate a Renal
Unit worklist from the Laboratory Host Computer System which will indicate: how many
samples received, barcode numbers, names of patients.
18. The Student Investigator will (on same day as analysis) retrospectively use the
generated worklist to search the Sysmex XE2100 analysers for Ret-He test results and the
host computer system for results of Ferritin and Transferrin Saturation Levels.
19. The barcode number of the patient and their test results will initially be recorded in
the student investigators laboratory handbook (the generated worklist will be discarded
into NHS Fife Confidential Waste)
20. The student investigator will record the test values into a coded SPSS (statistical
software) file for appropriate analysis.
21. The investigator will retrospectively match the test data with therapy regime data
provided by the Renal Unit (monthly meetings)
Pre Dialysis Patients: June 2010, July 2010, August 2010
(NB: Pre Dialysis Patients are tested 3 monthly so over period of study should get a baseline
sample from each consenting patient. Only those patients who are considered iron replete and
are placed on 5 week course of iron therpay will be further tested at their follow-up
appointments in order to measure response to therapy)
1. Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test,
clotted (yellow topped) for Ferritin and clotted (yellow topped)sample for Transferrin
Saturation Levels
2. Renal Unit Staff label samples and complete request form:
Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of
new Ret He test to FBC analysis) and Ferritin (routine request)
Biochemistry section ticked for : All routinely requested Biochemistry tests (such as
Urea and Electrolytes) plus routine request for Transferrin Saturation Levels
3. Sample and Requests sent to Fife Area Lab for Analysis
The project will be carried out within NHS Fife Area Laboratory Haematology Department and
will involve the use of NHS premises, facilities and staff (same process as points 6 - 21
above)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01449266 -
Safety and Dialysability of Dotarem® in Dialysed Patients
|
Phase 1 | |
Completed |
NCT01656135 -
Reference Group Trial for The ONE Study
|
Phase 4 | |
Completed |
NCT00807144 -
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT00238043 -
Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia
|
Phase 3 | |
Completed |
NCT02129881 -
The ONE Study UK Treg Trial
|
Phase 1/Phase 2 | |
Completed |
NCT01687699 -
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
|
Phase 4 |